Literature DB >> 10990092

Possible beneficial action(s) of glucose-insulin-potassium regimen in acute myocardial infarction and inflammatory conditions: a hypothesis.

U N Das.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10990092     DOI: 10.1007/s001250051497

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

1.  Glucose-insulin-potassium correlates with hemodynamic improvement in patients with septic myocardial dysfunction.

Authors:  Won-Young Kim; Moon Seong Baek; Young Shin Kim; Jarim Seo; Jin Won Huh; Chae-Man Lim; Younsuck Koh; Sang-Bum Hong
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

Review 2.  Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction.

Authors:  U N Das
Journal:  Mol Cell Biochem       Date:  2000-12       Impact factor: 3.396

3.  Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation.

Authors:  Undurti N Das
Journal:  J Inflamm Res       Date:  2010-12-02

Review 4.  Critical advances in septicemia and septic shock.

Authors:  U N Das
Journal:  Crit Care       Date:  2000-09-07       Impact factor: 9.097

Review 5.  Combination of aspirin with essential fatty acids is superior to aspirin alone to prevent or ameliorate sepsis or ARDS.

Authors:  Undurti N Das
Journal:  Lipids Health Dis       Date:  2016-11-25       Impact factor: 3.876

6.  Insulin and the critically ill.

Authors:  Undurti N Das
Journal:  Crit Care       Date:  2002-04-18       Impact factor: 9.097

Review 7.  Is insulin an endogenous cardioprotector?

Authors:  Undurti N Das
Journal:  Crit Care       Date:  2002-07-31       Impact factor: 9.097

Review 8.  Essential Fatty Acids and Their Metabolites in the Pathobiology of Inflammation and Its Resolution.

Authors:  Undurti N Das
Journal:  Biomolecules       Date:  2021-12-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.